Exhibit 16

	Page 1				
1	IN THE UNITED STATES DISTRICT COURT				
	FOR THE NORTHERN DISTRICT OF OHIO				
2	EASTERN DIVISION				
3					
4	IN RE: NATIONAL PRESCRIPTION MDL No. 2804				
	OPIATE LITIGATION Case No. 17-md-2804				
5					
6	This document relates to: Judge Dan				
	Aaron Polster				
7	The County of Summit, Ohio,				
	et al., v. Purdue Pharma, L.P.,				
8	et al.				
	Case No. 17-0P-45004				
9					
	The County of Cuyahoga v. Purdue				
10	Pharma, L.P., et al.				
	Case No. 17-0P-45090				
11					
	The City of Cleveland, Ohio v.				
12	Purdue Pharma, L.P., et al.				
	Case No. 18-OP-45132				
13					
14					
15					
16					
17	Videotaped Deposition of Allisyn Leppla				
18	Cleveland, Ohio				
19	January 15, 2019				
20	9:18 a.m.				
21					
22					
23					
24	Reported by: Bonnie L. Russo				
25	Job No. 3191877				

```
Page 2
        Deposition of Allisyn Leppla held at:
 1
 2
 3
 4
 5
 6
                     Napoli Shkolnik, PLLC
 7
                     55 Public Square
                     Suite 2100
 8
                     Cleveland, Ohio 44113
 9
10
11
12
13
14
        Pursuant to Notice, when were present on behalf
15
        of the respective parties:
16
17
18
19
20
21
22
23
24
25
```

```
Page 3
        APPEARANCES:
1
2
        On behalf of Cuyahoga County:
        SHAYNA E. SACKS, ESQ.
3
        NAPOLI SHKOLNIK, PLLC
        360 Lexington Avenue, 11th Floor
        New York, New York 10017
4
        212-397-1000
5
        ssacks@napolilaw.com
6
        On behalf of Johnson & Johnson and Janssen
        Pharmaceuticals, Inc.
7
        GIUSEPPE W. PAPPALARDO, ESQ.
        TUCKER ELLIS, LLP
8
        950 Main Avenue
        Suite 1100
9
        Cleveland, Ohio 44113
        216-592-5000
10
        gwp@tuckerellis.com
        On behalf of Walmart, Inc.
11
        KRISTIN S.M. MORRISON, ESO.
12
        JONES DAY
        North Point
13
        901 Lakeside Avenue
        Cleveland, Ohio 44114
        216-586-3939
14
        kmorrison@jonesday.com
15
        On behalf of Endo Pharmaceuticals, Inc., Endo
16
        Health Solutions, Inc., Par Pharmaceuticals,
        Inc. and Par Pharmaceutical Companies, Inc.:
17
        NICOLE LEIBOW, ESO.
        (Via Teleconference)
        ARNOLD & PORTER
18
        250 West 55th Street
19
        New York, New York 10019
        212-836-7838
20
        nicole.leibow@arnoldporter.com
        On behalf of Cardinal Health, Inc.:
21
        WILLIAMS & CONNOLLY, LLP
22
        PAUL E. BOEHM, ESQ.
        MELINDA JOHNSON, ESQ.
23
        725 12th Street, N.W.
        Washington, D.C. 20005
24
        202-434-5000
        pboehm@wc.com
25
        mkjohnson@wc.com
```

```
Page 4
        APPEARANCES (CONTINUED):
1
        On behalf of CVS Indiana, LLC and CVS Rx
        Services, Inc.:
3
        ZUCKERMAN SPAEDER, LLP
        DANIEL P. MOYLAN, ESQ.
        100 East Pratt Street, Suite 2440
4
        Baltimore, Maryland 21202
5
        410-332-0444
        dmoylan@zuckerman.com
6
        On behalf of AmerisourceBergen Drug
7
        Corporation:
        MICHAEL J. SALIMBENE, ESQ.
        (Via Teleconference)
8
        REED SMITH, LLP
9
        Three Logan Square, Suite 3100
        1717 Arch Street
        Philadelphia, Pennsylvania 19103
10
        215-241-7910
11
        msalimbene@reedsmith.com
        On behalf of McKesson Corporation:
12
        COVINGTON & BURLING, LLP
13
        JOHN W. ZIPP, ESQ.
        (Via Teleconference)
        One CityCenter
14
        850 Tenth Street, N.W.
15
        Washington, D.C. 20001
        202-662-6000
16
        jzipp.com
17
        On behalf of Mallinckrodt and Spec Gx, LLC:
        JOSH GOLDSTEIN, ESQ.
        ROPES & GRAY, LLP
18
        Prudential Tower
19
        800 Boylston Street
        Boston, Massachusetts 02199
20
        617-951-7000
        joshua-goldstein@ropesgray.com
21
                  -and-
        JESSICA R. SORICELLI, ESQ.
22
        ROPES & GRAY, LLP
        1211 Avenue of the Americas
        New York, New York 10036
2.3
        212-596-9000
24
        jessica.soricelli@ropesgray.com
25
        Also Present:
                       Daniel Russo, Videographer
```

		Pa	ige 5
1		CONTENTS	
2	EXAMINATION	OF ALLISYN LEPPLA	PAGE
3	BY MR. BOEHM	I	10
4	BY MR. GOLDS	TEIN	357
5	BY MR. MOYLA	ΔN	378
6			
7			
8		EXHIBITS	
9	Exhibit 1	Curriculum Vitae of	25
		Allisyn Leppla	
10		CUYAH_014186737-738	
11	Exhibit 2	E-Mail dated 2-6-14	44
		Attachment	
12		CUYAH_014181244-1248	
13	Exhibit 3	Cuyahoga County	114
		Board of Health	
14		2010 Annual Report	
15	Exhibit 4	Cuyahoga County	119
		Board of Health	
16		2012 Annual Report	
17	Exhibit 5	Article entitled	138
		"Cuyahoga County Aims	
18		to Reduce Overdose Fatalities'	'
		CUYAH_014188900-901	
19			
	Exhibit 6	Symposium Agenda	170
20		7-29-09	
		ODH_MDL 1st Production_000980-	-981
21	_ , , , , , _		
0.0	Exhibit 7	List of Attendees	172
22	T 1 '1 ' 0	ODH_MDL 3rd Production_00001-1	
23	Exhibit 8	E-Mail dated 1-17-14	178
2.4		CUYAH14211495-500	
24	Erchihit o	E Mail Chair	102
2 5	Exhibit 9	E-Mail Chain	183
25		dated 12-21-16	
		CUYAH_014195639-642	

1							
			Page	6			
1	EXHIBITS (CONTINUED):						
2	•	Ohio Prescription Drug	228				
_	HAIIIDIC IO	Abuse Task Force: Final	220				
3		Report Task Force					
2		Recommendations					
4		Recommendacions					
4	Erhihi+ 11	Article Draft	249				
_	EXHIDIC II		249				
5		CUYAH_014181983-987	260				
6	EXNIDIT 12	PowerPoint Deck	268				
_		Prescription for Prevention:					
7		Stop the Epidemic					
		2-6-13					
8							
	Exhibit 13	E-Mail Chain	292				
9		dated 8-13-14					
		CUYAH_014178416-420					
10							
	Exhibit 14	E-Mail Chain	331				
11		dated 9-24-15					
		CUYAH_014231470-471					
12							
	Exhibit 15	PowerPoint Deck	340				
13		Violence and Injury					
		Prevention Program					
14		CUYAH_014191053-073					
15	Exhibit 16	Data Brief, Volume One,	3 4 3				
		2016					
16		SUMMIT_000874244-248					
17	Exhibit 17	Undetermined risk factors	354				
		for fentanyl-related overdose					
18		deaths					
		Ohio 2015					
19		(EpiAid 2016-003)					
		- CUYAH-014244398-450					
20							
	Exhibit 18	Northeast Ohio Hospital	371				
21		Opioid Consortium					
		Goals and Objectives					
22		3					
23							
24	(Exhibits at	tached with transcript.)					
25	,						

Page 76

- A. That became a joint project in 2018.
- Q. Do you know why?

1

2.

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

2.2

2.3

2.4

25

- A. There was -- it -- it's my understanding that there were language changes. I -- I don't know if it was legislation, but there were language changes that mandated that ADAMHS Boards have control of county opiate task forces.
- Q. But in Cuyahoga County, that had not been true up until this past year, right?
 - A. That is my understanding.
- Q. Okay. When was the Cuyahoga County Opiate Task Force established?
 - A. Officially established in 2010.
- Q. When you say it was officially established in 2010 --
 - A. Uh-huh.
- Q. -- does that mean that there was something like this that existed prior to 2010 but it just wasn't official?
- A. Prior to 2010 we had a small group of individuals who primarily dedicated their time to drug take-back events. And so there was a smaller foundation of individuals from the organizations that are still currently

Veritext Legal Solutions

www.veritext.com

888-391-3376

Page 77 represented on the task force. 1 2. But in 2010 is when the Ohio 3 Department of Health partnered with FleishmanHillard, and it officially kicked off 4 the Cuyahoga County Board of Health. So in --5 6 in 2010 was the formal inception and establishment of the Opiate --When did --8 Q. 9 Α. -- Task Force. 10 Q. I'm sorry. 11 It's okay. Α. No. 12 When did the unofficial group start Q. 13 to do its work in terms of addressing the 14 opioid epidemic in Cuyahoga County prior to the 15 2010 establishment of the task force? 16 I don't recall precisely what year 17 that occurred. We began working in putting forth some efforts in 2006 -- as far back as 18 19 I don't know specifically what year the 20 other groups came together. 21 Were you involved in the efforts 2.2 here in Cuyahoga County to address the opioid 2.3 abuse epidemic that began in 2006? 2.4 Α. Yes. 2.5 Q. What were your responsibilities back